TIDMAVCT

RNS Number : 2828Y

Avacta Group PLC

04 December 2017

4 December 2017

Avacta Group plc

("Avacta", "the Group" or "the Company")

Posting of Annual Report and Notice of AGM

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Annual Report and Accounts for the year ended 31 July 2017 and the Notice of the 2017 Annual General Meeting are now available on the Company's website, www.avacta.com.

Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.

The Annual General Meeting will be held on Thursday 18 January 2018 at 10.00 a.m. at the offices of finnCap Limited, 60 New Broad Street, London EC2M 1JJ. Shareholders who plan to attend are requested, if possible, to register their attendance by email to investorevents@avacta.com.

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                        Tel: +44 (0) 844 
  Alastair Smith, Chief Executive         414 0452 
  Officer                                 www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                             Tel: +44 (0) 207 
  Geoff Nash / Giles Rolls - Nominated    220 0500 
  Adviser                                 www.finncap.com 
  Tim Redfern / Alice Lane / Nikita 
  Jain - Corporate Broking 
                                          Tel: +44 (0) 203 
  WG Partners                             705 9318 
  Nigel Birks / Nigel Barnes              Tel: +44 (0) 203 
  David Wilson / Claes Spang              705 9217 
                                          www.wgpartners.co.uk 
 Zyme Communications (Trade and          Tel: +44 (0)7787 
  Regional Media)                         502 947 
  Katie Odgaard                           katie.odgaard@zymecommunications.com 
 
  Yellow Jersey PR (Financial             Tel: +44 (0)7764 
  Media and IR)                           947137 
  Sarah Hollins                           avacta@yellowjerseypr.com

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGGGUPUPMGGC

(END) Dow Jones Newswires

December 04, 2017 06:03 ET (11:03 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.